Cargando…
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show a de novo resistance in most cases and a limited duration of response when response is achieved. We performe...
Autores principales: | Tétu, Pauline, Delyon, Julie, André, Jocelyne, Reger de Moura, Coralie, Sabbah, Malak, Ghanem, Ghanem E, Battistella, Maxime, Mourah, Samia, Lebbé, Céleste, Dumaz, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281633/ https://www.ncbi.nlm.nih.gov/pubmed/32344828 http://dx.doi.org/10.3390/cancers12051062 |
Ejemplares similares
-
Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020) -
Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019) -
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019) -
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023) -
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)